These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38706917)

  • 1. CS1 Expression Pattern in NK Cells and Correlated Factors in Plasma Cell dyscrasias: Implications for Elotuzumab Therapy and CAR-T Efficacy.
    Li C; Wang D; Xu Y; Mao X; Que Y; Li Z; Yu Q; Xu M; An N; Long X; Li C
    J Cancer; 2024; 15(10):3065-3075. PubMed ID: 38706917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
    Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL; Hughes T; Yu J; Rice A; Benson DM
    Cancer Immunol Immunother; 2013 Dec; 62(12):1841-9. PubMed ID: 24162108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
    Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ
    Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640
    [No Abstract]   [Full Text] [Related]  

  • 4. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
    Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
    Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
    van Rhee F; Szmania SM; Dillon M; van Abbema AM; Li X; Stone MK; Garg TK; Shi J; Moreno-Bost AM; Yun R; Balasa B; Ganguly B; Chao D; Rice AG; Zhan F; Shaughnessy JD; Barlogie B; Yaccoby S; Afar DE
    Mol Cancer Ther; 2009 Sep; 8(9):2616-24. PubMed ID: 19723891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab.
    Einsele H; Schreder M
    Ther Adv Hematol; 2016 Oct; 7(5):288-301. PubMed ID: 27695618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.
    Chu J; Deng Y; Benson DM; He S; Hughes T; Zhang J; Peng Y; Mao H; Yi L; Ghoshal K; He X; Devine SM; Zhang X; Caligiuri MA; Hofmeister CC; Yu J
    Leukemia; 2014 Apr; 28(4):917-27. PubMed ID: 24067492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.
    Malaer JD; Mathew PA
    Am J Cancer Res; 2017; 7(8):1637-1641. PubMed ID: 28861320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis.
    Rosenzweig M; Urak R; Walter M; Lim L; Sanchez JF; Krishnan A; Forman S; Wang X
    Cytotherapy; 2017 Jul; 19(7):861-866. PubMed ID: 28483281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.
    Pazina T; James AM; MacFarlane AW; Bezman NA; Henning KA; Bee C; Graziano RF; Robbins MD; Cohen AD; Campbell KS
    Oncoimmunology; 2017; 6(9):e1339853. PubMed ID: 28932638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary study of the fourth-generation CAR-T cells targeting CS1 in the treatment of refractory and recurrent multiple myeloma].
    Feng DD; Chen XH; Guo JJ; Wang KK; Zhang XM; Gao JM
    Zhonghua Zhong Liu Za Zhi; 2021 Jun; 43(6):657-665. PubMed ID: 34289557
    [No Abstract]   [Full Text] [Related]  

  • 12. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
    Danhof S; Rasche L; Mottok A; Steinmüller T; Zhou X; Schreder M; Kilian T; Strifler S; Rosenwald A; Hudecek M; Einsele H; Gerhard-Hartmann E
    Ann Hematol; 2021 Jun; 100(6):1537-1546. PubMed ID: 33575947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of elotuzumab and its potential in the treatment of multiple myeloma.
    Liu YC; Szmania S; van Rhee F
    Blood Lymphat Cancer; 2014 Jun; 2014(4):15-27. PubMed ID: 26005365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of [
    Ghai A; Zheleznyak A; Mixdorf M; O'Neal J; Ritchey J; Rettig M; DiPersio J; Shokeen M; Achilefu S
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1302-1311. PubMed ID: 33179150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
    Hsi ED; Steinle R; Balasa B; Szmania S; Draksharapu A; Shum BP; Huseni M; Powers D; Nanisetti A; Zhang Y; Rice AG; van Abbema A; Wong M; Liu G; Zhan F; Dillon M; Chen S; Rhodes S; Fuh F; Tsurushita N; Kumar S; Vexler V; Shaughnessy JD; Barlogie B; van Rhee F; Hussein M; Afar DE; Williams MB
    Clin Cancer Res; 2008 May; 14(9):2775-84. PubMed ID: 18451245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma.
    Golubovskaya V; Zhou H; Li F; Berahovich R; Sun J; Valentine M; Xu S; Harto H; Sienkiewicz J; Huang Y; Wu L
    Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective.
    Trudel S; Moreau P; Touzeau C
    Onco Targets Ther; 2019; 12():5813-5822. PubMed ID: 31410026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells.
    O'Neal J; Ritchey JK; Cooper ML; Niswonger J; Sofía González L; Street E; Rettig MP; Gladney SW; Gehrs L; Abboud R; Prior JL; Haas GJ; Jayasinghe RG; Ding L; Ghobadi A; Vij R; DiPersio JF
    Leukemia; 2022 Jun; 36(6):1625-1634. PubMed ID: 35422095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of NK Cell Receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in Cancer.
    Buller CW; Mathew PA; Mathew SO
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells.
    Chu J; He S; Deng Y; Zhang J; Peng Y; Hughes T; Yi L; Kwon CH; Wang QE; Devine SM; He X; Bai XF; Hofmeister CC; Yu J
    Clin Cancer Res; 2014 Aug; 20(15):3989-4000. PubMed ID: 24677374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.